Lupin’s stock saw a 2% increase following its acquisition of the Huminsulin® portfolio from Eli Lilly. This includes Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70, which Lupin had previously distributed in India.
The acquisition enhances Lupin’s position in the growing Indian diabetes market, addressing the increasing demand for effective insulin therapies. By adding these key insulin products, Lupin expands its offerings, reinforcing its commitment to providing accessible, high-quality diabetes treatment options.
Lupin Ltd. shares opened at ₹2,310.25, reaching a high of ₹2,359.00 and a low of ₹2,296.80. The stock has maintained its 52-week high of ₹2,359.00, while its 52-week low stands at ₹1,308.65.
In the meantime, it was revealed that Albuterol has become the second-largest contributor to the company’s US revenue.
The delay in generic competition for Albuterol has significantly benefited Lupin’s sales. According to Emkay, Amneal’s GProAir is expected to face delays, further extending Lupin’s market advantage. This news highlights Lupin’s strong position in the US respiratory market, making it an attractive option for investors.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
